Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00222495 · ClinicalTrials.gov registry record · NA
A Comparative Study of New Medications for Psychosis in Adolescents
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00222495 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 30 participants.
The verdict
NCT00222495, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The overall goal of this study is to determine the efficacy and tolerability of three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in the treatment of adolescents with psychosis. It is hypothesized that the three medications will be equally effective in reducing the symptoms of psychosis.
Interventions
- DRUG risperidone
- DRUG olanzapine
- DRUG quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00222495
The ClinicalTrials.gov registry entry for NCT00222495 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which risperidone is the first listed.
NCT00222495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00222495 about?
NCT00222495 is a clinical study titled "A Comparative Study of New Medications for Psychosis in Adolescents". The overall goal of this study is to determine the efficacy and tolerability of three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in the treatment of adolescents with psychosis. It is hypothesized that the three medications will be equally effective in reducing the s...
What is the current status of trial NCT00222495?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2002-08. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00222495?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG), quetiapine (DRUG).
Who is sponsoring clinical trial NCT00222495?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.